(1) Fuller M, Meike PJ, Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 2.
(2) Fabry Disease. National Organization for Rare Disorders. Accessed January 2018. Available at: https://rarediseases.org/rare-diseases/fabry-disease/ [https://c212.net/c/link/?t=0&l=es&o=2364689-1&h=1610235844&u...].
(3) Meikle PJ et al. Prevalence of Lysosomal Storage Disorders. JAMA. 1999. 281(3):249-54.
(4) Wraith JE et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008. 167(3):267-77.
(5) Martin R. Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome). PEDIATRICS. Volume 121, Number 2, February 2008.
(6) Young I. A clinical and genetic study of Hunter's syndrome. 2 Differences between the mild and severe forms. Journal of Medical Genetics, 1982, 19, 408-411.
(7) Guggenbuhl P, Grosbois B, Chals G. Gaucher disease. Joint Bone Spine. 2008; 75(2):116-124.
(8) Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008; 372:1263-71.
(9) Rosenberg JB, Kaminsky SM, Aubourg P, Crystal RG, Sondhi D. Gene therapy for metachromatic leukodystrophy. J Neuroscience Res. 2016;94(11);1169-79.
Logotipo - https://mma.prnewswire.com/media/817209/... [https://c212.net/c/link/?t=0&l=es&o=2364689-1&h=2621159793&u...]
CONTACTO: CONTACTO: Medios japoneses, Kazumi Kobayashi,kazumi.kobayashi@takeda.com, +81 (0) 3-3278-2095; Medios fuera de Japón,Tsuyoshi Tada, tsuyoshi.tada@takeda.com, +1 (617) 551-2933
Sitio Web: https://www.takeda.com/
